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S1. Identifying technical experts who were invited to participate in the CHNRI exercise 
The following Web of Science® search criteria were used to identify Group 1 technical experts:  
(neonatal OR newborn* OR neonate*) AND document type (Article) AND year published (2008-2012). In total, 
39,377 names were found and the top 100 were selected.  
For Group 2 technical experts, the same criteria were used with the addition of all the list of countries fall 
under the category of low and middle-income countries (LMIC). In total, 3,775 names were identified and the 
top 50 were selected.  
For the Group 3 technical experts, we conducted a search using the following criteria:  
(stillbirth*) AND document type (Article) AND year published (2008-2012). Of the 1,494 names returned in our 
search, the top 50 were selected.  
The 400 program experts were identified through databases maintained by Save the Children, Saving Newborn 
Lives (SNL). These experts were carefully chosen based on their experience in newborn health related 
programs in LMICs. Efforts were made to achieve a strong representation of government, UN and program 
experts working in LMICs. Each expert was only included once in either the most productive researcher or 
program expert group.  
S2. Characteristics of the expert group contributing the research questions 
Among the 600 invited experts, a total of 132 agreed to participate in the CHNRI exercise. The background 
characteristics are described in the main paper.  
S3. Compiling and refining questions 
A total of 394 research questions were submitted online. About half of the questions were related to 
intervention delivery, and a quarter to the domains of development and discovery, respectively. All questions 
were reviewed and edited, if necessary, by seven technical experts (SY, RB, JL, IR, SW, JPS, JM). During the 
process, efforts were made to maintain the sense of the original questions. A total of 41 questions were 
deleted because they were merely descriptive, unclear, too broad, too narrow, similar to another question, or 
already included among research outcomes that have been addressed in previous studies.  
Finally, 14 technical experts chosen from a pool of responders were invited to join 7 members of the 
management group for a two-day meeting in September 2012 to review and revise the questions. The meeting 
participants were divided into four groups, where they reviewed, edited to clarify, added any missing research 
questions, and/or deleted repetitive questions. The technical areas assigned to each group were on: (i) 
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neonatal infections, congenital abnormalities and non-classified questions; (ii) integrated care across maternal 
newborn and child health; (iii) “birth asphyxia” and stillbirth-related questions; and (iv) preterm birth. This 
process resulted in a total of 205 refined questions. Day 2 of the meeting was mainly devoted to finalizing the 
questions and the scoring criteria. After an agreement was given to the scoring criteria, 14 participants were 
asked to score the questions. Details of scoring criteria are provided in the main text.  
S4. Characteristics of the expert group scoring the research questions 
Among the 600 invited experts contacted, a total of 78 experts participated in the scoring exercise.  The 
background characteristics are described in the main paper.  
S5. The CHNRI methodology for setting priorities in health research investments. 
STAGE 1: Defining the context and criteria for priority setting 
Specifying the context a priori is a critical part of the CHNRI process, because priority scores for many research 
investment options may change substantially according to different contexts. The context for this exercise was 
defined to address research investment priorities beyond MDG4, i.e. by the year 2025.  
The context was specified by the management group as follows:  
• Burden of disease of interest: mortality, morbidity, birth outcomes, early development, short-term and long-
term health outcomes;  
• Population of interest: newborns (until 28 days);  
• Existing policy/target: improving newborn health and birth outcomes globally; 
• Level of urgency: high (because the relative importance of newborn deaths among child deaths is 
continuously increasing) 
• Time frame: to achieve detectable improvement in newborn health and birth outcomes by 2025; 
STAGE 2: Choice of technical experts, systematic listing and scoring of research investment options 
The process of the selection of the experts is described in the main paper and Supplementary online material 
(Sections S1-S4). The first task of the technical experts was to propose a large spectrum of research questions 
in a systematic way, belonging to three broad research themes: “Delivery”, “Development” and “Discovery”. 
We did not invite research ideas on “Description”, because we agreed that over the past several years most of 
the research issues from that domain have been addressed satisfactorily and gained global acceptance. The 
management group based at the WHO collected all the proposed ideas from 132 responders (of 600 invited) 
independently by e-mail. The process was open-ended and it initially yielded about 400 research questions. 
Then the list of research questions was consolidated and narrowed down to a manageable size for the scorers 
– i.e. 205 questions. During the pilot exercise, the management group limited the overlap between proposed 
ideas and ensured that the research questions were phrased in a way that would make the expected new 
knowledge apparent. We feel that the final list of 205 questions covers the wide spectrum of all possible 
questions. 
The second task for the experts was to score all research questions independently, according to the five agreed 
criteria (presented in Box 1). For each of the 205 research questions and each criterion, each expert answered 
a questions targeted to assess the likelihood of the proposed research to comply with the priority-setting 
criterion (see Box 1). This task was completed by all experts. The entire process was conducted and completed 
via e-mail between October and December 2012. Further information on methods related to this part of the 
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priority-setting process were presented elsewhere in greater detail.1,2 
STAGE 3: Community involvement - input from larger group of stakeholders 
CHNRI methodology ensures community involvement through incorporating the opinions and values from a 
broader group of stakeholders (e.g. expected recipients of the research, taxpayers who fund health research, 
health workers, journalists and media, experts in ethics, law, political science, etc.).1  Stakeholders lack 
expertise to directly decide research priorities, but their opinions and values can still be incorporated by 
weighing the chosen priority-setting criteria according to their perceived importance. In this exercise, we 
decided not to apply weights provided by the group of stakeholders most appropriate to this exercise (see 
Methods section in the main text). The reason for this is that this exercise is so broad, general and far-
reaching, that it would be difficult to identify an appropriate group of stakeholders that would have authority 
to represent all possible stakeholders. Instead, we presented the scores as they were computed, and allowed 
different possible users of the results of this exercise to apply weights and thresholds that would reflect their 
own views and values after the exercise is completed. Those weights and thresholds could be applied to 
intermediate scores, which we provided in all the tables with results, to adjust the overall priority scores and 
the ranking list. More detailed explanations on the rationale and methods for including stakeholders' opinions 
in the process are presented elsewhere (Kapiriri L). 
STAGE 4: Computation of "research priority scores" 
For each of the 205 research ideas, all the experts answered the questions listed in Box 1 by ‘Yes’ (1 point) or 
‘No’ (0 points). They were also allowed to declare an informed but undecided answer (0.5 points) or declare 
themselves insufficiently informed to answer the question (missing input). Thus, the proposed research 
questions received intermediate scores for each of the five criteria as "the proportion of maximum possible 
points scored when an answer was given" (i.e., excluding the missing input). Intermediate scores represent a 
direct measure of collective optimism of the 92scorers. Each of the 205 listed research questions received five 
intermediate scores (each ranging between 0-100%). The overall research priority score (RPS) was then 
computed as the mean of all five intermediate priority scores. The final list of research priorities with 
intermediate scores and overall research priority scores for all 205 proposed research questions is presented 
in Supplementary online material - S6. The exact scores given to all 205 research questions by individual 
experts to generate the ranking list are presented in Supplementary online material – S7. 
STAGE 5: Assessment of agreement between scorers 
CHNRI methodology has the ability to expose the issues of greatest agreement and controversy. This allows 
more focused discussion among experts following this exercise, and informs the investors and policy makers 
about the amount of controversy that surrounds each research question. The datasets that CHNRI 
methodology produces are not amenable to the usual Kappa agreement statistics, which has been discussed in 
detail elsewhere1. 
For each evaluated research investment option, AEA is informing us, for an average question, what proportion 
of scorers gave the same most frequent answer. This parameter satisfactorily accounts for missing answers, is 
unaffected by responses of ‘undecided’, and is also unaffected by the varying number of scorers per criterion 
and differences in scorer composition for the different criteria. 
STAGE 6: Assessing the advantages and limitations of the CHNRI methodology 
The applied CHNRI methodology proved to be helpful to systematically list and score a very large number of 
specific research questions, as shown recently in exercises conducted at national level in South Africa, and at 
global level for mental health research issues, childhood pneumonia, childhood diarrhoea, neonatal infections, 
“birth asphyxia”, primary health care, disability groups, etc.3-9 Other advantages of the CHNRI process include 
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its systematic nature, transparency, well defined (a priori) context and criteria chosen for discriminating 
between research investment options, a highly structured way in which relevant information is obtained from 
the scorers, independent scoring that limits influence of strong-minded individuals on the rest of the scorers, 
its informative and intuitive quantitative outputs and ability to expose points of greatest agreement and 
controversy. 
Still, the methodology is not free of several possible biases. Although the advantages mentioned above 
represent a serious attempt to deal with many issues inherent to a highly complex process of research priority 
setting, there are still concerns over the validity of the CHNRI approach and related biases. One of them is 
related to the fact many possible good ideas (“research questions”) may not have been included in the final list 
of proposed research questions that was scored by the experts. There is also a potential bias towards items 
that get the greatest media coverage. The spectrum of research questions listed initially in this exercise was 
derived through a systematic process, but it is not endless and it cannot cover every single research idea. 
Specific research methodologies (i.e. randomized clinical trials, etc.) are not mentioned because the research 
questions listed in that exercise are unlikely to be answered by a single well-defined study. Therefore, the 
CHNRI process aims to achieve reasonable coverage of the spectrum of possible ideas. After the completion of 
the exercise, approximate scores and ranks for some specific research questions that are missing in the initial 
systematic list could still be estimated – either by relating them to the most similar questions on the list, or by 
having those missed questions scored by a single expert (or by a group), using the CHNRI framework and then 
comparing the computed score to all other scores received for the originally listed research options. 
Another concern over the CHNRI process is that its end product represents a possibly biased opinion of a very 
limited group of involved people. In theory, a chosen group of experts can have biased views in comparison to 
any other potential groups of experts. However, the number of people globally who possess enough 
experience, expertise and knowledge on this issue to be able to judge a very diverse spectrum of research 
questions is rather limited (although certainly much larger than the group that we eventually selected). If one 
thinks of this “global pool of technical experts” as the whole population that could theoretically be used to 
solicit expert opinion on the questions that need to be asked, we then selected a “sample” from that 
population, based on their track record in research on newborn health and birth outcomes. Given that the 
“sample” of the experts chosen for this exercise (92 persons) was the largest and the most diverse to ever 
conduct a CHNRI exercise, while the number of experts in this neglected health problem globally is not large, 
we doubt that there would be considerable differences in the composition of the initial list of questions (or 
results of the scoring process) if some other group of experts had been selected. 
Apparently, CHNRI methodology is not free of bias that results from the choice of the experts, and different 
groups of experts may indeed have quite different opinions. However, the larger and more diverse the group 
of chosen experts (as in this case), the less likely is that the results of their scoring would significantly deviate 
from the output of any other large and diverse expert group, chosen from a limited “pool of global technical 
experts on newborns”. 
STAGE 7: Validation of the CHNRI methodology 
Fundamentally, the CHNRI methodology combines two ideas: 
(i) “Principal component analysis” - a statistical technique which reduces a very complex system of large 
number of variables to a smaller number of relatively independent “principal components” which still capture 
a sizeable proportion of variation in the system; by defining a set of 5 “criteria”, CHNRI process effectively 
reduces a notoriously complex and multi-dimensional task of priority setting, which could be approached 
through an almost infinite number of “lenses”, into an exercise where the 5 most important (and reasonably 
independent) criteria for priority setting are clearly defined. They can even be weighted afterwards, in order of 
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their importance to the users. 
(ii) “The wisdom of crowds” – this refers to the process of taking into account collective opinion of a group of 
individuals rather than a single expert (or small number of experts) to answer a question, because it has been 
shown that the average of collective guesses are nearly always closer to the truth than any expert judgement. 
The pre-requisites for this process to work are: (i) Diversity of opinion (each person should have private 
information even if it's just an eccentric interpretation of the known facts); (ii) Independence (people's 
opinions aren't determined by the opinions of those around them); (iii) Decentralization (people are able to 
specialize and draw on local knowledge); and (iv) Aggregation (some mechanism exists for turning private 
judgments into a collective decision – in this case, the CHNRI method). 
The validation of the CHNRI method based on the exercises conducted to date showed: (i) extraordinary 
stability (correlation coefficients of over 90%) of scores given to same questions by the same experts in 
different points in time; (ii) almost identical scores of the same question scored by a larger group multiple 
times (score always falls within +1.7 points on a scale 0-100); and (iii) Monte Carlo simulations in random sub-
samples of the larger group of scorers showed that the probability that the outcomes of the exercise could be 
substantially different if another group of experts conducted the scoring becomes incredibly small as soon as 
each criterion is scored by more than 17-23 rational persons with some knowledge of the problem; (iv) change 
of the context of the exercise leads the same group of experts to assign significantly different scores to the 
same research questions. 
In this paper, we used 92 technical experts to score each criterion. Thus, given the well-defined context for this 
CHNRI exercise and a set of simple YES/NO questions, it is entirely improbable that any other group of rational 
individuals with some knowledge of the problem, no matter of their background or selection, would ever reach 
dramatically different conclusions than our group did.  
Although this may seem counter-intuitive to some critics, this is the basic property of the „wisdom of 
crowds“ phenomenon (for more details please see an excellent book by James Surowiecki: The Wisdom of 
Crowds: Why the Many Are Smarter Than the Few and How Collective Wisdom Shapes Business, Economies, 
Societies and Nations), which CHNRI uses as its fundamental principle. Once that each individual gets a right to 
express judgement that is treated equally as the judgement of any other individual, then the personal biases 
that those individuals bring into the process tend to cancel and dilute each other regardless who the 
participants are. What is left is an information based on accumulated knowledge, lifetime experience and 
common sense of those who took part – which is the result of the CHNRI process.  
In comparison to other methods for setting priorities, in “expert panel”-type processes one very loud vote has 
a potential to heavily bias the process, resulting in shameful inequity and snowballing support for some issues 
at the expense of the others, a situation which we are observing today. We recently conducted Delphi and 
CHNRI exercises in parallel to compare them. This happened during the large GAPPS meeting (“Global action 
plan for prematurity and stillbirth”) sponsored by The Gates Foundation. Nine working groups were defining 
priorities using Delphi-type process, while three working groups were using CHNRI method. At the end of the 
conference, the rapporteurs from Delphi groups realised that it was simply unfeasible to have a discussion on 
all possible research options and keep in mind all their pros and cons at all times. Eventually, the group leaders 
ended up forwarding the ideas which they originally brought to the table and gained support for them from 
the rest of the group. In CHNRI groups, however, a process highlighted pros and cons of many competing 
ideas. More importantly, after the scoring was conducted, the top priorities were often surprising to the group 
- because they were sometimes the issues which have not been discussed at all, and few experts would have 
highlighted them as the leading priorities.  
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S6. An in-depth analysis of the reasons for divergence in overall research priority scores received by the 
similar research ideas. 
After the scoring was completed, we focused on several pairs (or triplets) of questions from the initial list that 
had similarities or overlap in their content, but received different overall scores. Those examples were 
particularly informative to understand what makes a research question more or less attractive as a research 
priority for the scorers. In this panel, we discuss several examples that are informative about the nature of the 
received scores and their sensitivity to the way the question is formulated. Supplementary table S8 highlights 
twelve pairs and three triplets of questions which have clear similarities in content, but also some differences 
in the way that the question was asked, that eventually led to different scores for particular criteria. We 
considered the difference in score for individual criterion by 5.0 points worth discussing. 
Example 1. The questions ranked 15 and 39 both suggested delivery research to improve postnatal care in the 
community, but while the first one was more general, the second one specifically mentioned traditional birth 
attendants as providers (TBA). Because of this, the latter question received lower scores for deliverability and 
potential impact, revealing the concerns of the scorers towards the capacity of TBAs to be engaged at larger 
scale and make a true difference. 
Example 2. The questions ranked 43 and 59 both suggested development research to increase capacity of 
health professionals at the facility level to improve neonatal outcomes; the first one did not specify the modes 
of training, while the second one suggested interned-based and mobile phone-based approaches. Because of 
this, the second question scored higher on answerability – presumably because it was easier for the scorers to 
envisage the mode of training; however, it scored lower on impact and equity, because the scorers didn’t see 
those specific tools as potentially most feasible in low-resource settings. 
Example 3. The questions ranked 10 and 61 both proposed delivery research to improve scale up of Kangaroo 
mother care for preterm and low birth weight newborns; the first was relevant to all contexts, while the 
second implied access to facilities and proposed studying long-term outcomes such as school performance. 
Because of those two differences, the latter question received less collective optimism towards effectiveness, 
deliverability, potential impact and the effect on equity. 
Example 4. The questions ranked 12 and 23 both suggested to evaluate effectiveness and cost of “follow-up” 
care (“extra care”) for preterm and low birth weight newborns; the first one was focused on the community 
level, and the second one on newborns that were discharged from a facility. As the basic underlying idea is the 
same, and it is delivered in community in both questions, the scores hardly differ – apart from the equity 
criterion, where it is clear that the latter research would only benefit newborns with access to facilities. 
Example 5. The questions ranked 72 and 92 both suggested research to improve quality of facility-based 
newborn care; the first one suggested doing this at the referral-level facility, and the second one at the district 
hospital facility. Both questions received very similar scores, but the former one was considered more 
answerable than the latter one. 
Example 6. The questions ranked 1 and 9 both suggested delivery research to simplify neonatal resuscitation 
program to reduce perinatal asphyxia; the first offered to study the role of education, implementation, quality 
improvement and system changes, while the latter one suggested a specific intervention of making bags and 
masks accessible to trained birth attendants. The first question out-performed all other suggested research 
questions, while the second one was also ranked very highly; however, it was inferior in terms of 
answerability, efficacy, deliverability and potential impact, but it did better in its predicted effect of equity – 
presumably because the intervention is particularly suitable for low-resource settings. 
Example 7. The questions ranked 38 and 40 both suggested evaluating effectiveness and cost of training 
community health workers to treat neonatal sepsis in the community with oral antibiotics – the only difference 
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was that the first question suggested 3rd generation cephalosporins and the second one suggested amoxicillin. 
This difference was clearly insufficient for the scorers to provide a notably different score against any of the 
criteria – although amoxicillin was considered slightly more deliverable, presumably because it is more widely 
available. 
Example 8. The questions ranked 73 and 87 both suggested nutritional interventions to prevent congenital 
disorders, but the first specified folic acid and iodine, while the latter didn’t mention any specific nutritional 
intervention. Clearly, the only difference was in the likelihood of efficacy related to proposed research; the 
first question had mentioned two specific intervention of proven efficacy, so it scored higher against that 
criterion. 
Supplementary table S8 offers several further examples where it becomes more apparent where did the 
differences in research priority scores between the 205 research questions arise from. In Tables 1-3 in the 
main text, we decided to omit research questions from these similar pairs of questions that received the lower 
score, in order to promote more ideas at the top of the rankings, rather than presenting the same idea with a 
slight modification twice. This is indicated by the asterisk in the column with overall research priority scores 
and a footnote. 
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S7. Full list of 205 research priorities ranked by overall research priority score. 
RAN
K 
RESEARCH QUESTIONS DOMAIN TOTA
L 
SCOR
E 
CONFIDENCE 
INTERVAL 
AGREEMENT 
BETWEEN 
SCORERS 
ANSWERA
BLE? 
EFFICACY
? 
DELIVERA
BLILITY? 
IMPACT? EQUITY? 
1 Simplified neonatal resuscitation program delivered 
by trained health worker in reducing neonatal deaths 
due to perinatal asphyxia 
Delivery 90 85 - 91 77 96 91 94 77 92 
2 Approaches to scale up worker skills in preventing 
and managing asphyxia 
Delivery 88 83 - 89 74 96 91 89 75 86 
3 Simple clinical algorithms to identify and refer 
neonates with signs of infection by CHW and 
consequently reduce newborn mortality 
Delivery 86 83 - 89 72 92 92 92 66 88 
4 Promote exclusive breastfeeding in low-resource 
contexts to reduce neonatal infections and mortality 
Delivery 85 79 - 89 72 94 89 86 69 86 
5 Training of CHWs in basic newborn resuscitation in 
reducing morbidity and mortality due to perinatal 
asphyxia 
Delivery 83 78 - 86 67 94 84 84 64 88 
6 Community-based initiation of Kangaroo Mother 
Care to reduce neonatal mortality of clinically stable 
preterm and low birth weight babies 
Develop
ment 
82 78 - 86 64 89 88 88 59 84 
7 Scale up administration of injectable antibiotics at 
home and first level facilities to newborns with signs 
of sepsis to reduce neonatal mortality 
Delivery 80 74 - 84 66 86 87 81 69 77 
8 Facility based initiation of Kangaroo Mother Care or 
continuous skin-to-skin contact 
Delivery 80 71 - 84 62 90 82 84 62 81 
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9 Impact of chlorhexidine application to the cord in 
facility births and in low NMR setting to reduce 
neonatal infections and neonatal mortality 
Delivery 80 70 - 83 67 91 85 89 52 81 
10 Quality of care during labour and birth in reducing 
intrapartum stillbirths and reduce neonatal mortality 
and disability 
Delivery 79 71 - 82 65 83 84 82 72 75 
11 Evaluate the effectiveness and cost of  "extra care" 
for preterm/LBW babies at community level  by 
trained community health workers including 
identification, additional home visits, supportive 
referral etc. in reducing neonatal morbidity and 
mortality in settings with poor accessibility to facility 
care 
Delivery 79 70 - 82 63 87 87 81 62 81 
12 Evaluate the effectiveness and cost of including 
newborn care as part of integrated community case 
management (ICCM) programs in improving 
newborn survival 
Delivery 79 70 - 83 57 90 85 82 61 77 
13 Evaluate approaches to improve community based 
postnatal care (e.g. home visits) within the context of 
existing health system 
Delivery 79 71 - 81 63 86 82 85 59 82 
14 Evaluate the effectiveness and cost of parental 
education on practices to prevent newborn 
infections at home, including recognition of neonatal 
infection and care seeking for it 
Delivery 79 70 - 82 64 85 81 85 60 81 
15 Develop and evaluate the effectiveness and cost of a 
minimum package of essential interventions and 
commodities that must be available at every birth to 
ensure safety of babies 
Delivery 79 72 - 84 63 82 82 82 66 80 
16 Evaluate the effectiveness and cost of approaches 
(eg notification systems) to improve  early postnatal 
home visit  coverage (in the first 24 hours of life) in 
odrer to improve maternal and newborn outcomes 
Delivery 78 69 - 82 62 90 84 84 51 84 
17 Evaluate the effectiveness and cost of community 
midwives or other 'skilled' community-based cadres 
to reduce overall neonatal mortality in settings 
Delivery 78 72 - 82 64 86 88 82 56 80 
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where facilities are commonly overcrowded or 
inaccessible 
18 Evaluate effectiveness and cost of provision of clean 
delivery kits and capacity building of traditional birth 
attendants in reducing incidence of neonatal 
infections 
Delivery 78 71 - 83 66 85 80 84 56 85 
19 Evaluate effectiveness, cost, safety and sustainability 
of provision of antenatal corticosteroid for reducing 
preterm deaths at lower levels of the health system 
either pre-referral or where referral is not possible 
Delivery 78 72 - 83 60 91 83 80 60 75 
20 Evaluate the effectiveness and cost of approaches to 
increase coverage of clean delivery practices in 
facilities 
Delivery 78 71 - 80 63 86 83 89 64 66 
21 Develop and evaluate the  effectiveness and cost of a 
package of community follow-up care for preterm 
and low birth weight newborns after discharge from 
a health facility 
Delivery 77 69 - 81 60 88 87 82 58 73 
22 Evaluate innovations (e.g. mobile technology) that 
would enable community based workers to reach 
newborns promptly after birth for assessment of 
danger signs and referral 
Delivery 77 70 - 81 63 93 83 80 56 74 
23 Design and evaluate different approaches for 
training to standardize and sustain skills in 
identification and case management of newborns 
with infections 
Delivery 77 70 - 81 60 89 84 81 62 69 
24 Evaluate the accuracy of community health workers 
in detecting a limited number of high risk conditions 
/ danger signs in pregnant women that require 
delivery at a health facility 
Develop
ment 
77 70 - 80 61 91 83 81 53 77 
25 Evaluate the effectiveness, cost and sustainability of 
conditional cash transfers in increasing coverage of 
antenatal care, skilled birth attendance and 
postnatal care 
Delivery 77 67 - 79 52 87 85 76 57 78 
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26 Evaluate approaches to scale up effective 
community-based participatory approaches to 
promote maternal and newborn health (through 
increased awareness, preventive health strategies, 
home-based monitoring and improved care-seeking) 
Delivery 76 69 - 84 59 84 84 78 57 78 
27 Evaluate approaches to improve quality of facility-
based intrapartum and immediate/early postnatal 
care for mothers and newborns (e.g., audit, “drills,” 
intrapartum and pre-discharge checklists) 
Delivery 76 68 - 80 60 88 85 86 59 63 
28 Identify and address the main barriers for 
implementation of programmes to prevent mother 
to child transmission of HIV in different low-resource 
settings 
Delivery 76 70 - 80 63 88 85 83 47 77 
29 Compare the effectiveness and cost of improving 
families' illness recognition and care-seeking for 
newborn illness versus active home visits in 
increasing the coverage of treatment for sick 
newborns 
Delivery 75 68 - 79 59 87 76 81 54 79 
30 Evaluate the effectiveness of a program in improving 
pregnancy outcomes through reducing the time 
between identification of a danger sign and arrival at 
a health facility  e.g. using mobile technology, 
establishing a district-wide transport plan, and 
coordinating an appropriate referral response 
Delivery 75 67 - 81 60 84 82 72 59 79 
31 Identify and address the main barriers for 
implementation of programmes to promote use of 
impregnated bednets in different low-resource 
settings to reduce the burden of congenital malaria, 
stillbirth, preterm and low birth weight 
Delivery 75 68 - 79 59 86 86 85 45 72 
32 Identify the components of the referral mechanism 
for women requiring emergency obstetric care which 
have a key impact on perinatal outcomes  (For 
example mode of transport, woman's position during 
transfer, alertness of the receiving facility before her 
arrival, accompaniment by health professional) 
Delivery 75 64 - 78 58 90 77 78 55 73 
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33 Evaluate effectiveness and cost of perinatal audits to 
improve quality of care in health facilities and 
improve fetal and neonatal outcomes 
Develop
ment 
74 67 - 79 58 90 83 80 53 63 
34 Design and evaluate a “First 1000 day” nutritional 
package (preconception, pregnancy, and first two 
years after birth) targeted for the poorest families to 
increase maternal weight  and the linear growth of 
the infants through 2 years of age. 
Delivery 74 66 - 77 59 85 79 70 53 81 
35 Develop and evaluate simple, cost effective 
strategies for intrapartum monitoring to enhance 
timely referral to improve fetal and neonatal 
outcomes 
Develop
ment 
74 67 - 79 57 88 83 76 56 66 
36 Evaluate the effectiveness and cost of training 
community health workers to recognize and treat 
neonatal sepsis at home with oral antibiotics (such as 
third generation cephalosporins) when referral is not 
possible, on neonatal mortality. 
Develop
ment 
74 62 - 78 57 85 77 75 54 77 
37 Evaluate the effectiveness of Traditional Birth 
Attendants carrying out early postnatal home visits 
for newborns who were born at home in improving 
newborn health outcomes 
Delivery 73 66 - 78 59 85 78 74 48 80 
38 Evaluate effectiveness of oral amoxicillin at home, 
with supervised home visits, for treatment of 
neonatal pneumonia 
Develop
ment 
73 64 - 78 58 82 76 80 52 76 
39 Evaluate the effectiveness and cost of various 
approaches (direct observation, mannequins, 
scenarios with hyper-local videos, scenarios alone, 
among others) for sustaining newborn resuscitation 
skills of CHWs 
Delivery 73 65 - 77 55 87 79 79 50 69 
40 Evaluate the effectiveness and cost of using mobile 
technology (mHealth) to improve quality of care of 
mothers and newborn babies at peripheral centres 
and in the community 
Delivery 73 66 - 77 57 88 78 76 51 70 
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41 Develop and evaluate the impact of models for 
strengthening capacity of health professionals in 
caring for neonates in peripheral hospitals and lower 
level health facilities on improving neonatal 
outcomes 
Develop
ment 
73 63 - 77 54 79 79 77 57 72 
42 Evaluate effectiveness and cost of an intervention 
package to prevent and manage perinatal asphyxia 
delivered by community health workers to reduce 
newborn mortality and morbidity 
Develop
ment 
72 64 - 77 55 81 74 75 56 75 
43 Evaluate the effectiveness and cost of approaches to 
increase coverage of clean delivery practices in 
homes 
Delivery 72 66 - 79 54 78 73 78 57 76 
44 Develop low-cost devices for facility care of 
newborns (e.g. CPAP, syringe drivers, IV giving sets, 
phototherapy, oxygen condensors, saturation 
monitoring, incubators, ventilators, therapeutic 
hypothermia technology) and test their effectiveness 
at various levels of the health system 
Develop
ment 
72 65 - 76 53 82 78 73 61 67 
45 Evaluate the effectiveness and cost of community 
health workers or TBAs to facilitate referral and 
increase families' compliance with referral 
Delivery 72 63 - 75 56 80 76 75 52 78 
46 Evaluate behavioural change communication 
approaches to promote messages on early initiation 
of breastfeeding and exclusive breastfeeding up to 
180 days 
Delivery 72 61 - 76 57 83 75 76 53 73 
47 Evaluate the effectiveness and costs of surfactant in 
reducing preterm morbidity and mortality in low and 
middle income countries 
Develop
ment 
72 65 - 78 56 83 83 75 56 63 
48 Evaluate effectiveness and cost of using community 
health workers to act as the first link in the referral 
chain connecting women in labour to the formal 
health care system in increasing skilled attendance 
and reducing intrapartum stillbirths and 
deaths/disability due to perinatal asphyxia 
Delivery 72 64 - 75 55 83 73 70 57 77 
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49 Develop and evaluate effectiveness of needle free 
antibiotics delivery to treat neonatal sepsis 
Develop
ment 
72 64 - 76 53 88 77 80 49 64 
50 Develop and evaluate strategies to increase correct 
use of partograph, linked to appropriate action 
Delivery 71 63 - 76 49 82 81 80 51 63 
51 Evaluate the effectiveness, cost and safety of CPAP 
to decrease neonatal mortality and morbidity in 
preterm infants in health care facilities in low 
resource settings 
Delivery 71 62 - 76 53 86 83 78 53 57 
52 Evaluate the effectiveness of strategies  to integrate 
neonatal care with immunization programs to 
improve newborn survival and health 
Delivery 71 63 - 74 57 83 73 77 49 71 
53 Design and evaluate an intervention package for 
identification and treatment of neonatal jaundice in 
resource-limited settings 
Delivery 71 66 - 75 62 90 85 82 34 62 
54 Evaluate the effectiveness and cost of innovative 
dosing devices (e.g. needle free, nasal, sublingual) 
for antenatal corticosteroids in preventing mortality 
and morbidity due to preterm birth 
Develop
ment 
71 61 - 74 50 83 75 78 51 66 
55 Develop low cost, stable surfactant with novel 
modes of administration (e.g. nasal delivery) in order 
to increase use and availability of surfactant for 
preterm babies at risk of RDS 
Discover
y 
71 62 - 73 49 82 82 77 51 61 
56 Develop and test effectiveness and cost of innovative 
methods of training (such as combinations of 
internet-based plus face to face training, simulators, 
mobile applications) to increase the capacity and 
skills of newborn and maternal care personnel in 
developing countries and improve maternal, fetal 
and neonatal outcomes 
Develop
ment 
70 64 - 75 55 84 80 76 49 63 
57 Evaluate community-based pregnancy registration 
system to promote safe home delivery and 
immediate newborn care practices, including 
appropriate referral for life-threatening 
Delivery 70 63 - 73 53 81 73 74 51 72 
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complications 
58 Evaluate the effect of post-discharge Kangaroo 
Mother Care  for preterm and low birth weight 
babies on health and survival outcomes in low and 
middle income countries, including long-term 
outcomes such as school performance 
Delivery 70 62 - 74 53 86 73 75 48 67 
59 Develop and evaluate easy-to-use devices for 
community-level neonatal resuscitation  (to be 
delivered by community health workers/ traditional 
birth attendants) 
Develop
ment 
70 60 - 74 50 76 74 74 52 72 
60 Evaluate the effectiveness and cost of approaches 
involving parents  in caring for their preterm babies 
in hospitals  to improve quality of care, reduce time 
to discharge and improve newborn outcomes 
Delivery 70 63 - 74 57 85 77 82 43 62 
61 Evaluate approaches to improve effectiveness of 
integrated maternal and newborn care at facility and 
community levels (e.g. reducing distance between 
delivery room and neonatal care areas, team 
approach) in reducing  adverse birth outcomes 
Delivery 70 62 - 74 52 82 75 72 53 67 
62 Evaluate effectiveness of approaches for early 
identification of complications of labour and real-
time communication of birth attendants with skilled 
practitioners at regional facilities for advice, referral 
and transport 
Develop
ment 
69 59 - 74 50 82 73 72 49 71 
63 Evaluate acceptability and effectiveness of 
intermittent facility based kangaroo mother care 
(KMC) for preterm and low birth weight babies 
compared to continuous KMC or 24 hour incubator 
care in improving neonatal outcomes. 
Develop
ment 
69 60 - 73 53 82 77 78 47 62 
64 Evaluate effectiveness and cost of strategies for 
simplified antibiotics treatment of sepsis at the 
facility to allow an earlier discharge with further 
outpatient care 
Develop
ment 
68 62 - 74 54 81 75 81 45 60 
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65 Develop and evaluate effectiveness and costs of 
easy-to-use low-cost devices to monitor maternal 
and newborn health (for example, blood pressure 
and glucose during pregnancy, warming devices, 
diagnostics) or facilitate provision of care in facilities 
and homes 
Develop
ment 
68 62 - 76 54 80 76 76 44 65 
66 Develop and evaluate a simplified algorithm for 
resuscitation of preterm babies in low resource 
settings 
Develop
ment 
68 59 - 74 52 76 76 73 51 66 
67 Evaluate the impact of programs designed to reduce 
anaemia in pregnant women (e.g. iron-folic acid 
supplementation, food fortification and growing and 
eating green leafy vegetables) in reducing the 
incidence of prematurity, intrauterine growth 
restriction and other adverse birth outcomes 
Delivery 68 60 - 74 54 81 68 77 42 73 
68 Evaluate the effectiveness and cost of a package of 
referral-level facility quality improvement in 
reducing neonatal mortality and long-term 
disabilities 
Delivery 68 60 - 73 50 80 75 75 54 56 
69 Evaluate methods to reduce nosocomial infections 
for all newborns in facility care 
Delivery 68 60 - 72 55 83 80 81 49 46 
70 Develop and evaluate improved technologies for 
large-scale food fortification programmes (e.g. folic 
acid, iodine) to prevent congenital disorders 
Develop
ment 
68 60 - 72 51 80 79 74 39 66 
71 Evaluate the impact of setting up sustainable 
neonatal and paediatric intensive care units in 
resource poor settings using simplified devices 
(CPAP, Inhaled surfactant, sepsis prevention and 
treatment) on neonatal outcomes 
Develop
ment 
67 59 - 73 50 76 81 63 58 58 
72 Evaluate the impact of family planning on reducing 
preterm births, small for gestational age, congenital 
disorders, stillbirths, and neonatal mortality 
Delivery 67 57 - 72 52 75 72 67 53 70 
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73 Evaluate the effectiveness, cost and safety of 
different maternal immunization delivery strategies 
with existing vaccines (e.g. flu, PC, Hib, Hep B, etc.) 
for prevention of newborn infections 
Develop
ment 
67 61 - 71 52 78 75 83 42 57 
74 Develop and evaluate low-cost devices for 
measurement of serum bilirubin at the point of care 
in resource-limited settings to improve management 
Develop
ment 
67 59 - 71 58 82 82 76 30 64 
75 Evaluate the effectiveness of a low cost locally 
produced alcohol or other antiseptic-based hand rub 
for use at home and in health facilities on incidence 
of neonatal infections 
Develop
ment 
67 59 - 71 50 82 71 73 42 65 
76 Develop and validate tools for identification of 
preterm infants in community settings by families 
and community health workers that are acceptable, 
feasible and cost-effective 
Develop
ment 
66 54 - 72 51 76 73 74 42 67 
77 Develop and evaluate regionalized perinatal service 
models, including detection of high-risk pregnancies 
and births to promote management at appropriate 
levels of care through a continuum of care between 
home, primary, and referral level 
Delivery 66 58 - 70 47 75 75 66 54 62 
78 Evaluate the effectiveness of community 
mobilization for "emergency preparedness" in 
improving neonatal outcomes. 
Develop
ment 
66 58 - 74 48 76 68 69 51 67 
79 Develop and evaluate optimal feeding strategies 
beyond the period of exclusive breastfeeding for 
preterm and LBW infants 
Develop
ment 
66 59 - 72 49 85 76 73 41 55 
80 Evaluate the potential adverse effects of community-
based treatment of neonatal infections, particularly 
changes in susceptibility of microorganisms 
Delivery 66 59 - 71 53 81 68 70 46 65 
81 Evaluate effectiveness and costs of maternal 
antibiotic prophylaxis to prevent early newborn 
infections 
Develop
ment 
66 58 - 71 51 84 73 74 44 54 
82 Design and evaluate accurate, yet affordable, 
methods to diagnose fetal distress in labour 
Discover
y 
66 57 - 71 49 78 71 73 50 56 
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83 Evaluate the effectiveness of low-cost electricity-free 
portable fetal heart monitors to improve 
identification and management of perinatal asphyxia 
and prevent stillbirths and early neonatal deaths 
Develop
ment 
65 58 - 71 53 78 74 73 43 59 
84 Assess effectiveness and cost of implementing a 
package of screening and treatment of syphilis in 
women of reproductive age to prevent stillbirths 
Delivery 65 59 - 70 57 80 78 74 30 62 
85 Evaluate approaches to improve nutritional intakes 
of women of reproductive age to prevent congenital 
disorders and improve other maternal and neonatal 
outcomes 
Develop
ment 
65 59 - 70 53 79 71 73 36 64 
86 Quantify the contributions of bacterial vaginosis, 
chorioamnionitis and sexually transmitted diseases 
(e.g. syphilis) to the burden of preterm birth, and 
evaluate the effect of treatment of these infections 
on prevalence of preterm birth and other adverse 
birth outcomes 
Develop
ment 
65 57 - 68 47 77 70 71 45 61 
87 Determine the effectiveness of oral neonatal vitamin 
A supplementation in reducing the incidence and/or 
severity of neonatal infections 
Develop
ment 
65 55 - 68 50 81 67 78 36 61 
88 Evaluate the feasibility and effectiveness of a lab-on-
a-chip diagnostics in reducing sepsis-specific 
neonatal mortality in low-income settings 
Develop
ment 
65 57 - 68 45 78 76 68 46 55 
89 Evaluate the effectiveness and cost of a package of 
district hospital interventions for improved care of 
newborn babies 
Delivery 64 53 - 69 49 73 73 71 51 54 
90 Determine and assess the minimum criteria (e.g., 
qualifications, training, job aid etc.) for frontline 
community health worker to be competent in 
managing neonatal resuscitation 
Delivery 64 56 - 69 51 77 70 69 39 66 
91 Evaluate the effectiveness of filtered sunlight to treat 
neonatal jaundice in communities with limited or no 
access to conventional phototherapy 
Develop
ment 
64 54 - 69 56 80 73 75 28 64 
19 
 
92 Develop and evaluate simple tools to predict (pre-
delivery) and identify (post-delivery) preterm birth 
and low birth weight for use by community health 
workers 
Delivery 64 55 - 69 51 77 67 70 43 62 
93 Evaluate effect and cost of strategies to deliver 
maternal and newborn care in humanitarian 
emergency contexts such as refugee and internally-
displaced populations 
Delivery 64 53 - 68 52 71 74 69 32 72 
94 Develop and evaluate new strategies for prevention 
and treatment of intrauterine growth restriction 
Discover
y 
64 51 - 68 46 77 70 67 45 59 
95 Evaluate the effectiveness and cost of individual on-
job mentorship/tutorship on skills acquisition and 
retention for frontline (first level health facility) 
health workers with respect to maternal and 
newborn care 
Delivery 63 55 - 70 46 74 69 66 46 62 
96 Develop and evaluate the effectiveness and cost of a 
package of preterm birth prevention interventions 
that can be implemented at scale 
Delivery 63 54 - 70 46 70 65 64 57 60 
97 Determine the optimal time for cord clamping in 
preterm infants, considering neonatal and maternal 
outcomes 
Develop
ment 
63 55 - 68 54 75 69 80 36 56 
98 Develop and evaluate behaviour change strategies to 
improve community involvement in prevention of 
stillbirths and neonatal deaths 
Delivery 63 53 - 70 47 71 64 65 45 69 
99 Evaluate the effectiveness of different types of 
partographs, including pictorial partograph, in 
improving maternal fetal, and neonatal outcomes 
Develop
ment 
63 54 - 71 47 81 69 70 40 53 
100 Evaluate effectiveness and cost of incentives to 
clinical caregivers to provide high quality care to 
mothers and newborns from socially disadvantaged 
and marginalized groups 
Delivery 63 53 - 67 46 74 69 60 40 70 
101 Develop novel tocolytic agents to delay or stop 
preterm labour, in order to reduce death/disability 
Discover
y 
63 54 - 68 42 72 69 72 48 51 
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102 Evaluate possible antenatal supplementation 
strategies to prevent early newborn sepsis e.g., zinc, 
vitamin D, vitamin A 
Develop
ment 
62 53 - 66 47 79 64 78 37 54 
103 Evaluate the effect of zinc as an adjunct to treatment 
of neonatal sepsis 
Develop
ment 
62 51 - 64 45 80 65 78 36 53 
104 Evaluate the effectiveness and cost of Maternity 
Waiting Facilities, particularly for women at higher 
risk of preterm birth, for increasing coverage of 
perinatal care and improving maternal and neonatal 
outcomes 
Develop
ment 
62 52 - 66 44 72 71 66 42 60 
105 Evaluate effectiveness and cost of a school-based 
program for adolescent girls  to reduce known risks 
for future pregnancy (age at first pregnancy, 
anaemia reduction, awareness of risk factors, birth 
preparedness) in improving birth outcomes 
Develop
ment 
62 54 - 69 50 75 64 71 38 62 
106 Evaluate the effectiveness and cost of text messages 
to improve management of newborn complications 
during the first week of life 
Delivery 62 55 - 67 47 79 66 72 42 50 
107 Evaluate impact of combined (integrated) 
educational programs in antenatal care, obstetric 
care, newborn resuscitation, essential newborn care 
and sick newborn care, compared with separate 
training on these topics, on maternal, fetal and 
newborn outcomes 
Develop
ment 
62 52 - 66 47 74 66 68 46 54 
108 Develop and evaluate a small, portable oxygen 
concentrator integrated with a pulse oximeter that 
allows automated regulation of oxygen flow to 
maintain oxygen concentration within a specified 
therapeutic range 
Develop
ment 
62 53 - 66 45 74 76 67 41 51 
109 Evaluate approaches to prevent pre-lacteal feeding Delivery 61 55 - 71 46 75 74 68 34 56 
21 
 
110 Evaluate the effectiveness of approaches to reduce 
inappropriate use of broad-spectrum antibiotics to 
treat newborn infections 
Delivery 61 53 - 67 52 79 75 68 39 46 
111 Evaluate the effectiveness and cost of different 
health education models (e.g. school-based, 
community-based) in delivering the curriculum for 
promoting sustained health changes in young 
women and their families 
Delivery 61 52 - 69 44 73 66 64 44 59 
112 Improve the basic newborn resuscitation algorithm 
(decision points and timing) through a series of 
randomized trials 
Develop
ment 
61 51 - 67 44 68 69 68 45 58 
113 Evaluate the effectiveness and cost of training birth 
attendants on the appropriate use of uterotonics 
prior to birth in reducing intrapartum stillbirths,  
neonatal deaths and adverse maternal outcomes 
Develop
ment 
61 52 - 67 45 74 71 66 40 55 
114 Identify major causal pathways and risk factors for 
antepartum stillbirth to find potential intervention 
targets 
Discover
y 
61 52 - 66 43 73 65 64 46 56 
115 Investigate the pharmacokinetics of existing and 
emerging antibiotics so that they can be used to 
treat newborn infections in community and facility 
settings in the 1st week of life, particularly for 
preterm and LBW babies 
Develop
ment 
61 49 - 63 43 71 66 82 38 46 
116 Develop and evaluate effectiveness of novel point of 
care diagnostics for congenital syphilis that could be 
used in a low resource setting to improve 
management 
Discover
y 
60 53 - 64 49 79 70 70 24 59 
117 Evaluate the effectiveness of antenatal care clinics in 
promoting timely identification and care-seeking 
behaviour for newborns with jaundice. 
Delivery 60 55 - 69 54 79 69 67 31 57 
118 Identify novel antibiotic or other biological agents 
that could be used widely in treatment of neonatal 
infections 
Discover
y 
60 51 - 65 40 72 63 68 50 49 
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119 Evaluate the programmes of training of community 
health workers in identification, management and 
referral of congenital disorders 
Delivery 60 54 - 65 58 80 70 65 27 56 
120 Evaluate approaches to overcome financial barriers 
to the delivery of integrated newborn services 
Delivery 59 50 - 65 41 69 63 56 47 61 
121 Develop and evaluate new methods for the early 
identification of intrauterine growth restriction 
(including biomarkers), and predict abnormal 
postnatal growth and body composition 
Discover
y 
59 52 - 63 43 78 67 66 36 48 
122 Develop and evaluate the novel vaccines for 
maternal immunization (e.g. GBS, Klebsiella, E. Coli, 
Staph, etc.) for prevention of newborn infections 
Discover
y 
59 51 - 64 41 73 64 64 44 50 
123 Evaluate the effectiveness and cost of most feasible 
implementation strategies for the existing point of 
care diagnostics for congenital syphilis in the 
antenatal and newborn period that could be used in 
a low resource setting 
Develop
ment 
59 51 - 63 51 73 71 66 24 60 
124 Develop and evaluate strategies to prevent 
inappropriate use of potentially teratogenic 
medications during preconception, pregnancy and 
lactation 
Develop
ment 
58 46 - ## 49 70 102 59 22 39 
125 Evaluate the effectiveness of strategies to encourage 
women to monitor fetal movements and seek care if 
reduced movements, in reducing stillbirths 
Develop
ment 
58 51 - 65 46 76 64 63 36 52 
126 Evaluate if preterm birth can be delayed or averted  
with antioxidant and/or nutrient supplementation(s) 
e.g. Vitamin D, omega-3 fatty acids 
Discover
y 
58 48 - 63 42 74 62 66 39 50 
127 Evaluate the effectiveness and cost of administering 
an oral antibiotic to all neonates born at home who 
are considered to be high-risk in reducing early 
neonatal mortality 
Develop
ment 
58 49 - 65 42 66 60 59 42 63 
128 Develop and evaluate the effectiveness of strategies 
to reduce childhood blindness due to retinopathy of 
prematurity, particularly through safe oxygen 
Develop
ment 
58 49 - 61 49 73 71 68 28 47 
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management, in low resource settings 
129 Evaluate the effectiveness of oral probiotic 
supplementation (e.g. Bifidobacterium infantis and 
Lactobacillus acidophilus) in reducing incidence, 
duration and/or severity of neonatal infections 
Develop
ment 
58 48 - 62 44 79 65 68 35 41 
130 Examine the pathways by which pre eclampsia is 
associated with adverse birth outcomes including 
stillbirth and preterm birth and explore innovative 
moderating factors to delay or prevent these adverse 
outcomes 
Discover
y 
57 46 - 63 41 72 62 59 43 50 
131 Evaluate the effectiveness of teaching mothers 
appropriate ways of holding the baby for 
breastfeeding in improving initiation of exclusive 
breastfeeding and newborn survival and health in 
resource poor, high mortality settings 
Delivery 57 49 - 63 50 81 55 64 33 52 
132 Develop and evaluate the impact of strategies to 
reduce elective induction of labour and C-section 
without medical indication on prevalence of preterm 
birth 
Delivery 57 51 - 61 49 76 72 67 33 37 
133 Evaluate the impact of a program of promoting 
exclusive breast milk feeding to preterm babies, with 
provision of  human donor milk if mother's own milk 
own breast milk  is unavailable, on neonatal and 
child growth outcomes 
Delivery 57 50 - 62 47 74 68 57 36 51 
134 Evaluate the effectiveness of reduction of 
environmental exposures (e.g. indoor air pollution, 
agricultural products, occupational exposures) on 
adverse birth outcomes, including congenital 
conditions, stillbirth, low birthweight, and preterm 
birth 
Develop
ment 
56 49 - 61 44 71 64 60 36 52 
135 Examine interactions between preterm birth and 
pro-inflammatory processes of pregnancy (e.g. 
malaria, HIV, enteric disease) in order to inform 
intervention. 
Discover
y 
56 48 - 62 41 76 61 62 37 45 
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136 Evaluate the effectiveness and cost of varying cadres 
and skills mix for health workforce teams (e.g. 
physicians, midwives, nurses, patient attendants 
etc.)  to effectively deliver facility based 
interventions for newborn care 
Delivery 56 45 - 61 41 63 63 63 44 45 
137 Evaluate approaches to make therapeutic 
hypothermia for treatment of perinatal asphyxia 
(neonatal encephalopathy) safe and effective in low 
resource settings 
Delivery 55 46 - 61 42 67 68 58 39 46 
138 Evaluate the effectiveness of maternal lactoferrin 
supplementation, a preventative strategy for 
perinatal infection/inflammation, in preventing 
preterm birth 
Develop
ment 
55 46 - 60 38 75 62 64 31 45 
139 Evaluate the effectiveness and cost of strategies to 
enhance social accountability and community 
demand for better quality of care at birth including 
in the context of conditional cash transfers 
Develop
ment 
55 46 - 61 34 60 57 58 37 63 
140 Evaluate safety and efficacy of fortification of breast 
milk for preterm and low birth weight babies in 
improving growth, survival and cognitive 
development 
Develop
ment 
55 46 - 62 47 72 64 63 33 43 
141 Evaluate the effectiveness and cost of a kit 
containing basic life saving equipment given to 
women who are likely to deliver at home on 
stillbirths, neonatal mortality and morbidity. 
Develop
ment 
55 43 - 60 44 71 57 59 35 54 
142 Evaluate efficacy of various progestational 
compounds on spontaneous preterm birth, including 
evaluations of different agents and modes of 
delivery (e.g. vaginal micronized progesterone, gel, 
IM 17-alpha hydroxyprogesterone caproate), 
in various geographic and risk populations (e.g. short 
cervix, prior preterm birth, reproductive tract 
infections, systemic infections) 
Develop
ment 
55 46 - 58 38 72 65 63 36 41 
143 Evaluate the effectiveness of BCG vaccine at birth to 
newborns (and to the subset of LBW newborns) in 
reducing neonatal and under five mortality 
Develop
ment 
55 45 - 62 45 70 62 67 29 48 
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144 Evaluate the effectiveness, cost and safety of 
different rubella immunization delivery strategies for 
prevention of congenital rubella infections 
Develop
ment 
55 48 - 63 52 71 67 69 20 47 
145 Evaluate the effect of timing (preconception period 
vs. first or second trimester of pregnancy) for 
micronutrient supplementation to prevent 
congenital disorders 
Develop
ment 
55 47 - 61 47 70 64 63 29 49 
146 Evaluate whether preconception nutritional 
supplementation of mothers leads to long-term 
improvements in health and development in the 
children 
Develop
ment 
55 46 - 62 45 68 58 62 33 53 
147 Develop new formulations of iron (or new medicines 
which when given with iron) that reduce side effects 
and increase the bioavailability when given as 
supplement to preterm babies 
Develop
ment 
55 48 - 62 42 70 59 68 30 46 
148 Evaluate efficacy of treating neonatal/congenital 
malaria with injectable artesunate given orally (with 
and without a first phase of intravenous treatment) 
to prevent  mortality and long term disability 
Delivery 55 47 - 59 38 71 63 62 27 50 
149 Evaluate the acceptability, benefits and risks of 
introducing portable ultrasound scanning into the 
community 
Develop
ment 
55 46 - 59 47 72 59 59 32 51 
150 Evaluate the effectiveness and cost of implementing 
newborn screening and management for common 
inherited metabolic disorders in preventing mortality 
and long term disability 
Delivery 54 48 - 59 58 80 70 60 21 40 
151 Evaluate and compare the effectiveness and cost of 
pre-service vs. in-service training on newborn care 
skills acquisition, use and retention 
Delivery 54 42 - 59 42 67 66 65 32 40 
152 Evaluate the effect of improved management of 
neonatal sepsis on long term developmental 
outcomes 
Develop
ment 
54 46 - 63 43 63 62 63 34 49 
153 Develop strategies for early identification of 
newborns at risk of neglect and evaluate 
interventions to prevent adverse outcomes in these 
Delivery 54 45 - 58 45 70 57 54 30 58 
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newborns 
154 Evaluate which components of neonatal 
resuscitation (stimulation, suction and ventilation) 
are most effective in reducing intrapartum-related 
deaths when performed by first level care providers 
Develop
ment 
53 41 - 59 41 59 57 63 37 51 
155 Determine the factors that shape the amount of 
public financing that the governments of countries 
with high neonatal mortality devote to newborn 
survival 
Delivery 53 45 - 59 36 66 51 52 42 55 
156 Evaluate methods to improve diagnosis and care of 
babies born with common congenital disorders in 
developing countries 
Delivery 53 46 - 58 56 76 62 61 24 44 
157 Develop and evaluate novel approaches to prevent 
mother to the baby infection transmission, e.g., 
maternal showering, vaginal douche, antiseptic wash 
of baby 
Develop
ment 
53 46 - 59 43 72 62 56 32 45 
158 Identify the mechanisms behind the socioeconomic 
gradient in the risk of preterm birth, intrauterine 
growth restriction and other adverse birth outcomes 
in order to inform strategies to reduce inequalities 
Discover
y 
53 44 - 57 38 61 53 53 36 64 
159 Develop new adjuvant therapies to therapeutic 
hypothermia for management of asphyxiated 
newborns 
Discover
y 
53 44 - 59 40 71 66 54 32 40 
160 Evaluate the effect of interventions to reduce 
prenatal exposure to environmental tobacco smoke 
(second-hand smoke) on the risk of preterm birth, 
intra uterine growth restriction, stillbirth and 
neonatal death 
Develop
ment 
52 44 - 58 44 65 58 58 32 49 
161 Identify the facilitating and inhibiting factors that 
govern the financial support of international donor 
agencies to newborn health in order to increase the 
amount and sustainability of funding 
Delivery 52 42 - 60 34 62 53 53 44 50 
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162 Evaluate the effectiveness and cost of lifestyle 
modification interventions in the mother (e.g. diet, 
smoking and exercise) in reducing stillbirths and 
improving neonatal outcomes 
Develop
ment 
52 42 - 58 39 64 59 54 36 49 
163 Evaluate strategies for control of alcohol use in 
women of reproductive age to prevent fetal alcohol 
spectrum disorders 
Delivery 52 44 - 57 52 72 65 62 19 43 
164 Evaluate the effectiveness of community-based use 
of pulse oximetry to reduce mortality and morbidity 
of sick and/or small newborns. 
Develop
ment 
52 44 - 58 41 66 58 55 28 53 
165 Identify and validate early novel biochemical 
markers of perinatal asphyxia and hypoxic ischemic 
encephalopathy in order to inform earlier targeted 
interventions 
Discover
y 
52 43 - 59 39 69 61 54 35 41 
166 Evaluate the efficacy of a package of interventions 
for intrauterine fetal resuscitation in low and middle 
income countries in reducing intrapartum stillbirths 
and early neonatal deaths 
Develop
ment 
51 40 - 57 37 63 56 57 38 42 
167 Develop and evaluate the feasibility of using novel 
wireless pulse oximeter probes to measure fetal 
oxygenation 
Develop
ment 
51 42 - 56 46 67 60 59 27 44 
168 Evaluate the effectiveness and cost of using 
ultrasound devices with automatic estimation of 
gestational age in ANC on perinatal outcomes 
Delivery 51 41 - 55 49 78 57 52 28 38 
169 Describe political and bureaucratic (rather than 
scientific or health systems) factors that facilitate or 
obstruct the scale-up of newborn survival 
interventions in countries with high neonatal 
mortality 
Delivery 51 41 - 55 36 59 51 45 41 57 
170 Develop simplified assessment tools for mother's 
mental health state, delineate the effects on 
newborn health and test interventions to improve 
neonatal and child development outcomes 
Delivery 50 42 - 55 44 64 56 56 24 53 
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171 Evaluate the impact of home pregnancy testing on 
gestational age at enrolment for ANC and seeking 
care from skilled health providers 
Develop
ment 
50 43 - 58 46 66 59 53 25 47 
172 Investigate appropriate indications for use of vaginal 
pessary for the prevention of spontaneous preterm 
birth and evaluate its efficacy 
Develop
ment 
50 42 - 53 34 65 55 53 34 42 
173 Develop and evaluate low cost tools to identify 
manageable congenital disorders at community and 
primary health care level 
Develop
ment 
50 42 - 57 50 64 63 58 19 44 
174 Evaluate efficacy of erythropoietin added to 
therapeutic hypothermia, to enhance 
neuroprotection in late preterm and full term infants 
with neonatal encephalopathy, in improving 
neonatal outcomes 
Discover
y 
49 40 - 55 36 65 62 53 28 37 
175 Evaluate the effectiveness and cost of 
licensure/relicensure schemes for providers and 
accreditation/reaccreditation schemes for healthcare 
facilities to improve quality of services provided 
through both public and private systems 
Delivery 49 39 - 54 37 65 53 52 35 40 
176 Develop neuroprotective and neuroregenerative 
therapies to reduce developmental brain injury in 
preterm infants 
Discover
y 
49 40 - 55 36 63 53 49 38 41 
177 Evaluate the effect of reduced physical workload 
during pregnancy on the occurrence of adverse birth 
outcomes 
Develop
ment 
48 43 - 56 44 63 55 49 26 48 
178 Identify novel adjuvants / immunomodulators that 
could be used widely in treatment of neonatal 
infections 
Discover
y 
48 37 - 53 36 65 54 51 33 38 
179 For pathogens that cross the placental barrier, 
determine if there is a common mechanism(s) used 
by several pathogens that could become a target for 
development of future interventions to prevent 
neonatal infections 
Discover
y 
48 37 - 53 37 57 57 52 34 40 
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180 Evaluate the effectiveness of administering an oral 
antibiotic to all neonates born at home in reducing 
early neonatal mortality 
Develop
ment 
47 38 - 54 41 58 48 44 35 53 
181 Validate the use of most promising candidate 
biomarkers that can guide the initiation and/or 
duration of antibiotic therapy for neonatal sepsis 
(e.g. CD64, interleukins, etc.) to improve 
management 
Develop
ment 
47 39 - 51 41 68 57 47 30 32 
182 Evaluate the effectiveness of allopurinol, given to 
pregnant women with signs of fetal hypoxia, to 
improve newborn morbidity and later morbidity 
Discover
y 
47 36 - 55 36 62 53 56 28 35 
183 Develop and evaluate the effect of community and 
facility level strategies that raise the profile of the 
neonate as a human being with a right to live to 
change the rooted social norm that accepts neonatal 
deaths 
Develop
ment 
46 36 - 52 40 53 46 51 31 51 
184 Develop novel molecular tests to assess placental 
function, including that in post-date pregnancies in 
odrer to reduce stillbirths, early neonatal deaths and 
later disability 
Discover
y 
46 36 - 49 41 64 56 45 30 35 
185 Evaluate whether pre-conceptional nutritional 
supplementation of mothers leads to epigenetic 
changes in offspring DNA (measured in placenta, 
umbilical cord and blood). 
Discover
y 
46 37 - 52 40 67 53 47 26 37 
186 Develop and utilize non-invasive assessments to 
image and characterize the normal development of 
the placenta across gestation and changes in adverse 
pregnancy states 
Discover
y 
45 36 - 50 40 65 49 45 29 38 
187 Develop and evaluate novel micronutrient strategies 
to reduce cerebral damage related to perinatal 
asphyxia in order to reduce death and disability 
Discover
y 
45 35 - 51 38 58 42 54 29 39 
188 Identify and validate genomic, proteomic, and 
epigenetic biomarkers and biochemical markers in 
maternal blood, amniotic fluid, saliva, vaginal 
secretions etc. for prediction of preterm birth, 
Discover
y 
44 36 - 49 36 56 52 48 31 35 
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intrauterine growth restriction, and other adverse 
pregnancy outcomes 
189 Evaluate the effectiveness of strategies to promote 
safe sleep environments to reduce the incidence of 
SIDS, accidental suffocation, and other sudden 
unexpected deaths in infancy 
Delivery 44 36 - 49 48 62 55 53 18 31 
190 Understand the changes in the normal microbiome 
in pregnancy and contrast to that in pregnancies 
complicated by adverse outcomes (preterm birth, 
stillbirth, preeclampsia) 
Discover
y 
44 35 - 49 39 64 49 48 25 32 
191 Discover unique inflammatory signature of most 
common pathogens associated with neonatal 
infections to develop and evaluate novel tailored 
interventions to prevent pathogen specific 
inflammatory response 
Discover
y 
43 34 - 49 35 54 52 47 28 34 
192 Evaluate the effectiveness of a novel, fish oil based 
lipid emulsion, in reducing liver damage associated 
with parenteral nutrition in neonates with congenital 
gastrointestinal disorders 
Discover
y 
43 34 - 48 41 64 52 51 18 29 
193 Evaluate effectiveness and cost of cervical cerclage 
for prevention of preterm birth in low- and middle-
income countries, including development and 
assessment of ultrasound technologies that are 
affordable and appropriate for use in low-resource 
settings 
Develop
ment 
42 33 - 47 37 55 51 44 28 34 
194 Discover unique inflammatory signature of most 
common pathogens associated with neonatal 
infections in order to tailor the existing interventions 
to prevent pathogen specific inflammatory response. 
Discover
y 
41 31 - 48 37 54 47 46 25 35 
195 Evaluate geographic variation in the microbiome of 
pregnant women and validate potential biomarkers 
that may predict preterm birth and specific 
phenotypes 
Discover
y 
41 33 - 47 39 58 44 43 25 36 
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196 Evaluate the effectiveness of use of room air 
compared to 100% oxygen during resuscitation of 
term newborns born at home in improving short-
term newborn outcomes 
Develop
ment 
40 32 - 47 45 51 46 43 21 40 
197 Develop and evaluate the efficacy of growth 
stimulating factors or other novel approaches to 
prevent broncho-pulmonary-disease for preterm 
babies 
Develop
ment 
40 32 - 46 40 54 49 47 21 27 
198 Evaluate public educational strategies for prevention 
of inherited inborn errors of metabolism and single-
gene disorders 
Develop
ment 
38 33 - 47 44 56 42 45 15 34 
199 Develop and evaluate interventions to reduce 
oxidative stress to prevent placental senescence and 
evaluate their effects on stillbirth and other adverse 
birth outcomes 
Discover
y 
38 28 - 44 38 54 44 40 24 28 
200 Find biomarkers to identify newborns who do not 
benefit from therapeutic hypothermia for perinatal 
asphyxia 
Discover
y 
34 26 - 42 42 51 39 37 19 23 
201 Evaluate the effectiveness of promoting 5 instead of 
3 years birth interval on preventing stillbirths and 
improving newborn survival and health 
Develop
ment 
34 25 - 41 47 45 36 33 22 33 
202 Develop and evaluate interventions to reduce 
psychosocial stress to prevent placental senescence 
and evaluate their effects on stillbirth and other 
adverse birth outcomes 
Develop
ment 
34 26 - 40 42 44 37 41 18 30 
203 Assess the validity of maternal blood nucleic acid 
testing for detection of fetal genetic anomalies to 
improve management 
Develop
ment 
34 28 - 40 47 53 42 35 14 23 
 
The questions originally ranked 5th and 12th were omitted from this table because it was a variant of question that already received a higher overall score.  
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Name Affiliation 
Peter Aaby Prof, DMSc, Bandim Health Project, Indepth Network, Guinea-Bissau 
Ishag Adam Prof, MD, PhD, Faculty of Medicine, University of Khartoum, Sudan 
Ramesh Kant Adhikari  Prof, MD, Kathmandu Medical College, Nepal 
Namasivayam 
Ambalavanan  
MD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA  
Shams El Arifeen Dr, DrPH, Centre for Child and Adolescent Health, International Centre for Diarrhoeal Disease Research, Bangladesh 
Dhana Raj Aryal Prof, Department of Neonatology Paropakar Maternity and women's Hospital, Nepal 
Sk Asiruddin MD, MSc, TRAction Bangladesh Project,  University Research Co., LLC 
Abdullah Baqui Prof, PhD Johns Hopkins Bloomberg School of Public Health, USA. 
Aluisio JD Barros Centro de Pesquisas Epidemiológicas, Universidade Federal de Pelotas, Brazil 
Christine S. Benn Prof, MD, PhD, DMSc, Research Center for Vitamins and Vaccines, Statens Serum Institut, and University of Southern 
Denmark/Odense University Hospital, Denmark 
Vineet Bhandari MD, Program in Perinatal Research, Yale University School of Medicine, USA 
Shinjini Bhatnagar PhD, Pediatric Biology Centre, Translational Health Science and Technology Institute, India 
Sohinee Bhattacharya  Dr MBBS PhD University of Aberdeen, UK  
Zulfiqar A Bhutta  MB,BS, PhD, Center of Excellence in Women and Child Health, the Aga Khan University, Karachi, Pakistan 
Robert E Black Prof, MD, Institute of International Programs, Johns Hopkins Bloomberg School of Public Health, USA. 
Hannah Blencowe MRCPCH, The London School of Hygiene & Tropical Medicine, UK 
Carl Bose Prof, MD, The University of North Carolina at Chapel Hill School of Medicine, USA 
Justin Brown Thrasher Research Fund, USA 
Christoph Bührer Prof, MD, Department of Neonatology, Charité University Medical Center, Germany 
Wally Carlo University of Alabama at Birmingham, USA 
Jose Guilherme Cecatti Prof, MD PhD, Department of Obstetrics and Gynaecology, School of Medical Sciences, University of Campinas, Brazil 
Po-Yin Cheung Prof, PhD, FRCP (Can&Edin), Departments of Pediatrics, Pharmacology & Surgery, University of Alberta, Canada 
Robert Clark MD MPH, LDS Charities, USA 
Tim Colbourn PhD, University College London Institute for Global Health, UK 
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Agustin Conde-Agudelo  MD, MPH, PhD, Perinatology Research Branch, Eunice Kennedy Shriver National Institute of Child Health and Human 
Development/National Institutes of Health/Department of Health and Human Services, Bethesda, Maryland and Detroit, 
Michigan, USA  
Erica Corbett MSc, Independent consultant maternal health research, Rwanda 
Andrew E Czeizel Prof, MD, DoctSci, Foundation for the Community Control of Hereditary Diseases, Hungary. 
Abhik Das PhD, Biostatistics and Epidemiology, RTI International, USA 
Louise Tina Day Dr, MRCPCH MRCOG, LAMB Integrated Rural Health & Development, Bangladesh 
Carolyn Deal Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases National Institute of 
Health, USA 
Ashok Deorari All India Institute of Medical Sciences, India 
Uğur Dilmen Prof, Pediatrics and Neonatology, Yıldırım Beyazıt University Medical Faculty, Turkey 
Mike English MD, Nuffield Department of Medicine & Department of Paediatrics, University of Oxford, UK and KEMRi-Wellcome Trust 
Research Programme, Nairobi, Kenya 
Cyril Engmann MD, Newborn Health, Family Health Division, The Bill & Melinda Gates Foundation and the University of North Carolina Schools 
of Medicine and Public Health, USA 
Fabian Esamai Prof, PhD, Moi University, School of Medicine, Kenya 
Caroline Fall Prof MD, International Paediatric Epidemiology; Affiliations: Medical Research Council Lifecourse Epidemiology Unit, University 
of Southampton, UK 
Donna M Ferriero Prof, MD, Department of Pediatrics, UCSF Benioff Children's Hospital, USA 
Peter Gisore  School of Medicine, Child Health and Pediatrics, Moi University, Kenya 
Tabish Hazir Prof, MD Children's Hospital, Pakistan Institute of medical sciences, Pakistan 
Rosemary D. Higgins MD, Eunice Kennedy Shriver NICHD Neonatal Research Network, Pregnancy and Perinatology, Branch, National Institute of 
Health, USA 
Caroline SE Homer  Prof, Centre for Midwifery, Child and Family Health, University of Technology, Sydney, Australia 
Dewan Md Emdadul 
Hoque 
Dr, MPH, Centre for Child and Adolescent Health, International Centre for Diarrhoeal Disease Research, Bangladesh 
Lorentz Irgens University of Bergen and Norwegian Institute of Public Health, Norway 
Mohammad Tajul Islam MPH, Japan International Cooperation Agency (JICA), Bangladesh 
Joseph Johnson DrPH Save the Children, USA 
Martias Joshua  MB,BS MPH, Zomba Central Hospital, Ministry of Health, Malawi 
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William Keenan  MD, Saint Louis University, USA 
Soofia Khatoon  Paediatrics and Head of Department Shaheed Suhrawardy Medical College, Bangladesh. 
Helle Kieler Centre for Pharmacoepidemiology, Karolinska Institute, Sweden 
Michael S. Kramer Prof, MD, Departments of Pediatrics and of Epidemiology, Biostatistics and Occupational Health, McGill University Faculty of 
Medicine, Montreal, Quebec, Canada 
Eve M Lackritz MD, Global Alliance to Prevent Prematurity and Stillbirth (GAPPS), USA 
Tina Lavender Prof, University of Manchester School of Nursing Midwifery & Social Work, University of Manchester, UK 
Laurensia Lawintono MSc Indonesian Midwives Association, Indonesia 
Richard Luhanga Save the Children, Malawi 
David Marsh MD, MPH, Save the Children, USA 
Douglas McMillan Prof, MD, Department of Paediatrics, Dalhousie University, Canada 
Patrick J McNamara MD, Departments of Paediatrics & Physiology, University of Toronto; Physiology & Experimental Medicine program, Hospital for 
Sick Children, Toronto, Canada 
Ben Willem J Mol  Prof,. MD PhD. Department of Obstetrics and Gynaecology, Academic Medical Centre Amsterdam, the Netherlands 
Elizabeth Molyneux  Prof, Paediatrics and Child Health, College of Medicine Malawi 
G. K. Mukasa International Baby Food Action Network, Uganda 
Miriam Mutabazi 0 MD, STRIDES for Family Health, Management Sciences for Health, Uganda 
Luis Carlos Nacul Dr MD PhD, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, UK 
Margaret Nakakeeto Kampala Children's Hospital Limited and Childhealth Advocacy International, Uganda  
Indira Narayanan  MD, United States Agency for International Development /Maternal and Child Health Integrated Program, USA. 
Bolajoko Olusanya FRCPCH, Centre for Healthy Start Initiative, Nigeria 
David Osrin  MRCP PhD, Wellcome Trust Senior Research Fellow in Clinical Science, Institute for Global Health, University College London, UK 
Vinod Paul Prof, PhD, All India Institute of Medical Sciences, India 
Christian Poets University of Tubingen, Germany 
Uma M. Reddy0 Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, USA 
Mathuram Santosham  Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, USA. 
Rubayet Sayed. Save the Children, Bangladesh 
Natalia E. Schlabritz- MD, PhD, Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, USA 
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Loutsevitch 
Nalini Singhal Prof, FRCPC, University of Calgary, Canada. 
Mary Alice Smith Environmental Health Science Department, University of Georgia, USA 
Peter G. Smith Prof, DSc, MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London , UK. 
Sajid Soofi  MD, Department of Pediatrics & Child Health, Women & Child Health Division, Aga Khan University, Pakistan 
Catherine Y. Spong Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, USA 
Shahin Sultana National Institute of Population Research and Training (NIPORT), Ministry of Health and Family Welfare, Bangladesh 
Antoinette K. Tshefu  Prof, PhD, Kinshasa School of Public Health, School of Medicine, University of Kinshasa, Democratic Republic of Congo  
Bel F. Van Prof, Department of Neonatology, University of Utrecht, The Netherlands 
Lauren Vestewig Gray MA, Institute for Global Health Technologies Rice University, USA 
Peter Waiswa MD, DrPH, Division of Global Health, Karolinska Institutet, Sweden 
Wei Wang Prof, MD, PhD, FFPH, School of Medical Sciences, Edith Cowan University, Australia and School of Public Health, Capital Medical 
University, China 
Sarah L A Williams Save the Children UK 
Linda L Wright MD, Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, USA 
Anita Zaidi Prof, Aga Khan University, Pakistan 
Yanfeng Zhang MSc, Department of Integrated Early Childhood Development, Capital Institute of Paediatrics, China. 
Nanbert Zhong Prof, MD, Developmental Genetics Laboratory, New York State Institute for Basic Research in Developmental Disabilities, USA 
Isabel Zuniga MD MPH, Médecins sans Frontières, Belgium 
 
  
36 
 
Supplementary table S9: Pairs (or triplets) of questions from the initial list that had similarities or overlap in their content, but received different overall scores. They were 
used of an in-depth analysis of the reasons for divergence in overall research priority scores received by the similar research ideas. The yellow cells highlight the differences 
in intermediate scores greater than 5.0 points, which were discussed in Box 1. 
RA
NK 
RPS RESEARCH QUESTIONS ANSW
ERABL
E? 
EFFI
CAC
Y? 
DELIVERA
BLILITY? 
IMPA
CT? 
EQ
UIT
Y? 
13 79 Evaluate approaches to improve community based postnatal care (e.g. home visits) within the context of 
existing health system 
85.6 81.5 84.5 59.2 82.3 
37 73 Evaluate the effectiveness of Traditional Birth Attendants carrying out early postnatal home visits for 
newborns who were born at home in improving newborn health outcomes 
84.8 77.6 74.4 48.0 80.2 
41 73 Develop and evaluate the impact of models for strengthening capacity of health professionals in caring for 
neonates in peripheral hospitals and lower level health facilities on improving neonatal outcomes 
78.7 79.0 77.2 56.6 71.8 
56 70 Develop and test effectiveness and cost of innovative methods of training (such as combinations of 
internet-based plus face to face training, simulators, mobile applications) to increase the capacity and skills 
of newborn and maternal care personnel in developing countries and improve maternal, fetal and neonatal 
outcomes 
83.9 80.0 75.6 49.1 63.1 
8 80 Facility based initiation of Kangaroo Mother Care or continuous skin-to-skin contact 90.5 81.9 84.4 61.6 81.0 
58 70 Evaluate the effect of post-discharge Kangaroo Mother Care  for preterm and low birth weight babies on 
health and survival outcomes in low and middle income countries, including long-term outcomes such as 
school performance 
86.3 72.6 75.3 48.2 67.3 
11 80 Evaluate the effectiveness and cost of  "extra care" for preterm/LBW babies at community level  by trained 
community health workers including identification, additional home visits, supportive referral etc. in 
reducing neonatal morbidity and mortality in settings with poor accessibility to facility care 
87.2 86.9 81.0 62.2 81.0 
21 78 Develop and evaluate the  effectiveness and cost of a package of community follow-up care for preterm 
and low birth weight newborns after discharge from a health facility 
88.0 86.6 81.9 57.6 73.5 
68 68 Evaluate the effectiveness and cost of a package of referral-level facility quality improvement in reducing 
neonatal mortality and long-term disabilities 
79.5 75.3 75.3 53.7 55.8 
89 64 Evaluate the effectiveness and cost of a package of district hospital interventions for improved care of 
newborn babies 
72.9 72.6 71.3 50.1 53.9 
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76 66 Develop and validate tools for identification of preterm infants in community settings by families and 
community health workers that are acceptable, feasible and cost-effective 
75.6 73.2 74.1 42.0 67.1 
92 64 Develop and evaluate simple tools to predict (pre-delivery) and identify (post-delivery) preterm birth and 
low birth weight for use by community health workers 
77.3 67.0 70.5 42.5 62.2 
1 90 Simplified neonatal resuscitation program delivered by trained health worker in reducing neonatal deaths 
due to perinatal asphyxia 
96.1 91.0 93.8 77.0 92.1 
(om
itte
d) 
82 Evaluate the effectiveness and cost of making a bag and mask accessible to trained individuals or teams 
attending births in reducing neonatal mortality 
85.9 80.6 86.1 58.8 96.2 
2 88 Approaches to scale up worker skills in preventing and managing asphyxia 96.0 91.5 89.3 75.1 85.7 
(om
itte
d) 
84 Evaluate the effectiveness and cost of training nurses/midwives in intrapartum fetal monitoring and 
neonatal resuscitation in reducing stillbirths and deaths/disability due to perinatal asphyxia 
93.6 89.0 91.4 65.1 80.0 
5 83 Training of CHWs in basic newborn resuscitation in reducing morbidity and mortality due to perinatal 
asphyxia 
94.3 84.1 84.1 63.8 87.8 
39 73 Evaluate the effectiveness and cost of various approaches (direct observation, mannequins, scenarios with 
hyper-local videos, scenarios alone, among others) for sustaining newborn resuscitation skills of CHWs 
86.8 79.4 78.6 50.2 69.1 
93 64 Evaluate effect and cost of strategies to deliver maternal and newborn care in humanitarian emergency 
contexts such as refugee and internally-displaced populations 
77.1 69.6 68.5 39.3 65.6 
10 79 Quality of care during labour and birth in reducing intrapartum stillbirths and reduce neonatal mortality 
and disability 
82.6 84.3 81.8 72.1 74.7 
50 71 Develop and evaluate strategies to increase correct use of partograph, linked to appropriate action 81.6 80.7 80.4 50.9 63.2 
33 74 Evaluate effectiveness and cost of perinatal audits to improve quality of care in health facilities and 
improve fetal and neonatal outcomes 
89.9 83.1 80.2 52.9 62.8 
35 74 Develop and evaluate simple, cost effective strategies for intrapartum monitoring to enhance timely 
referral to improve fetal and neonatal outcomes 
88.4 82.6 75.6 55.9 65.7 
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82 68 Design and evaluate accurate, yet affordable, methods to diagnose fetal distress in labour 78.3 70.7 72.6 50.2 67.9 
83 65 Evaluate the effectiveness of low-cost electricity-free portable fetal heart monitors to improve 
identification and management of perinatal asphyxia and prevent stillbirths and early neonatal deaths 
78.2 73.8 72.9 43.3 58.9 
14 79 Evaluate the effectiveness and cost of parental education on practices to prevent newborn infections at 
home, including recognition of neonatal infection and care seeking for it 
84.8 81.3 85.5 60.5 81.0 
29 76 Compare the effectiveness and cost of improving families' illness recognition and care-seeking for newborn 
illness versus active home visits in increasing the coverage of treatment for sick newborns 
86.9 76.5 81.5 53.9 78.7 
18 78 Evaluate effectiveness and cost of provision of clean delivery kits and capacity building of traditional birth 
attendants in reducing incidence of neonatal infections 
84.7 79.7 83.9 55.6 85.5 
43 72 Evaluate the effectiveness and cost of approaches to increase coverage of clean delivery practices in homes 77.8 72.7 77.8 56.7 76.2 
36 74 Evaluate the effectiveness and cost of training community health workers to recognize and treat neonatal 
sepsis at home with oral antibiotics (such as third generation cephalosporins) when referral is not possible, 
on neonatal mortality. 
84.7 77.1 75.0 53.7 77.2 
38 73 Evaluate effectiveness of oral amoxicillin at home, with supervised home visits, for treatment of neonatal 
pneumonia 
81.8 76.2 79.5 51.5 75.9 
70 68 Develop and evaluate improved technologies for large-scale food fortification programmes (e.g. folic acid, 
iodine) to prevent congenital disorders 
80.1 79.3 74.1 38.6 65.8 
85 65 Evaluate approaches to improve nutritional intakes of women of reproductive age to prevent congenital 
disorders and improve other maternal and neonatal outcomes 
78.7 71.4 73.5 35.7 64.5 
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